Phase 1 Thyroid Cancer Trial, Recruiting NCT07181720 Sponsor: Chongqing Precision Biotech Co., Ltd Condition: Thyroid Cancer
Back to Thyroid Cancer

Phase 1 Thyroid Cancer Trial, Recruiting

NCT07181720
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years old or older
  • You have been diagnosed with an advanced or metastatic solid tumor (a cancer that has spread), and lab testing has confirmed that your tumor strongly expresses a protein called CD70 (shown by a specific lab score called IHC 3+)
  • Your cancer has stopped responding to standard treatments, or you could not tolerate them — including certain targeted therapies, specific enzyme-blocking drugs, or anti-blood-vessel-growth treatments, as well as surgery, chemotherapy, radiotherapy, or other targeted therapies
  • At least one area of your cancer can be measured on a CT scan (meeting specific size requirements — confirm with trial site)
  • Your general health and ability to carry out daily activities is rated at a certain level by your doctor (called ECOG 0–2, meaning you are fully active to capable of basic self-care)
  • Your doctors expect you to live for at least 12 weeks
  • You have no history of severe mental health disorders
  • Your blood, heart, kidneys, and liver are functioning well enough, as shown by recent lab tests and a heart scan (confirm specific values with trial site)
  • Your blood oxygen level is at least 92% without needing extra oxygen
  • You are able to have blood drawn, with no medical reason preventing a blood collection procedure
  • If you are a woman who could become pregnant, you agree to use reliable birth control from when you sign up until one year after receiving the treatment
  • You (or your legal guardian) understand what the trial involves and are willing to sign a consent form agreeing to take part

Who may not be able to join:

  • You have previously received any treatment that targets the CD70 protein
  • You currently have active or symptomatic cancer that has spread to your brain or the lining around it (however, if your brain metastases were treated at least 4 weeks ago and are not getting worse, you may still be eligible — confirm with trial site)
  • You have taken part in another interventional clinical trial within the past 3 months, or recently received certain other experimental or approved drugs within specific time windows before the study procedures (confirm exact timeframes with trial site)
  • You received chemotherapy or targeted therapy within 2 weeks before your blood is collected (or within a certain number of half-lives of the drug, whichever comes first)
  • You have taken steroid medications (such as prednisone) at more than 10mg per day within the 2 weeks before your blood is collected, unless it is for a specific medical reason such as adrenal replacement or inhaled/topical use
  • You received a live vaccine within 4 weeks before the screening visit
  • You currently have an active infection that requires treatment, or had an uncontrolled infection within the week before screening
  • You have been diagnosed with another cancer in the past 3 years (exceptions may apply for certain treated skin cancers or cancers fully cured with no signs of return — confirm with trial site)
  • You have serious heart problems, such as severe heart failure, a heart attack or heart bypass surgery within the past 6 months, significant irregular heartbeats, unexplained fainting, or a serious heart muscle condition
  • You have an active or poorly controlled autoimmune disease, such as Crohn's disease, rheumatoid arthritis, lupus, or vasculitis
  • You have certain active viral infections including active Hepatitis B, Hepatitis C, HIV, or syphilis (confirm with trial site)
  • You still have significant side effects from previous cancer treatments that have not returned to near-normal levels (hair loss and mild nerve-related symptoms may be exceptions)
  • You have a history of serious blood clots (such as a pulmonary embolism) and are currently on blood thinners, or have experienced serious bleeding or lasting complications from blood clots
  • You are currently pregnant or breastfeeding
  • Your doctor believes there is another reason that makes it unsafe or unsuitable for you to join the trial

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Donglai Lv, MD, The 901 Hospital of Joint Logistics Support Force of People Liberation Army

Phone: +8613655600090

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Chongqing Precision Biotech Co., Ltd
Registry
ClinicalTrials.gov
Start date
12 September 2025
Est. completion
31 March 2028

Where this trial is recruiting

🇨🇳 China

Primary endpoints

To evaluate the safety of CAR-T cell preparations in the treatment of CD70-positive advanced malignancies [Safety and Tolerability]; Obtained the recommended dose and infusion regimen of CAR-T cells for the treatment of patients with CD70-positive advanced malignancies [Safety and Tolerability]

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov